

© Springer International Publishing Switzerland 2016

Dear Reader,

As we approach the end of 2016, and publish our final issue of *Drugs & Therapy Perspectives* for the year, I wish to reflect on another successful year for the journal and for others in the Adis Premier journal portfolio, and to thank all who have contributed to *Drugs & Therapy Perspectives* over the past 12 months.

The past year has seen a substantial increase in the number of original research and other externally written articles being published in *Drugs & Therapy Perspectives*. Overall, this change appears to be a positive one, with many such articles being highly downloaded. Our in-house written *Adis Drug Q&A* articles and other article types also continue to popular with our readership. As of September 2016, *Drugs & Therapy Perspectives*' top downloaded articles from SpringerLink this year included:

- Castaldo RS. Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series. *Drugs Ther Perspect.* 2016;32(4):162–9. doi:[10.1007/s40267-016-0288-3](https://doi.org/10.1007/s40267-016-0288-3)
- Whelan B, Musters E, Murray A., et al. Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands. *Drugs Ther Perspect.* 2016;32(3):119–30. doi:[10.1007/s40267-015-0275-0](https://doi.org/10.1007/s40267-015-0275-0)
- Cohen M, Stallone F, Pallin DJ. Injectable promet-hazine: a risky drug of questionable efficacy. *Drugs Ther Perspect.* 2016;32(7):294–6. doi:[10.1007/s40267-016-0296-3](https://doi.org/10.1007/s40267-016-0296-3)
- K.A. Lyseng-Williamson. Vedolizumab in moderately to severely active ulcerative colitis or Crohn's disease:

a guide to its use. *Drugs Ther Perspect.* 2016;32(7):265–75. doi:[10.1007/s40267-016-0311-8](https://doi.org/10.1007/s40267-016-0311-8)

- Adis Medical Writers. Effective treatment of attention-deficit hyperactivity disorder also helps control symptoms of comorbid oppositional defiant disorder. *Drugs Ther Perspect.* 2016;32(3):104–9. doi:[10.1007/s40267-015-0269-y](https://doi.org/10.1007/s40267-015-0269-y)
- Adis Medical Writers. Stevens–Johnson syndrome and toxic epidermal necrolysis: early recognition and prompt management may reduce mortality. *Drugs Ther Perspect.* 2016;32(6):238–43. doi:[10.1007/s40267-016-0294-5](https://doi.org/10.1007/s40267-016-0294-5)
- Behr J, Lyseng-Williamson KA. Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU. *Drugs Ther Perspect.* 2016;32(2):50–9. doi:[10.1007/s40267-015-0273-2](https://doi.org/10.1007/s40267-015-0273-2)
- Adis Medical Writers. Beware of hepatotoxicity risk with new oral anticoagulants (NOACs). *Drugs Ther Perspect.* 2016;32(3):113–8. doi:[10.1007/s40267-015-0274-1](https://doi.org/10.1007/s40267-015-0274-1)
- Shirley M, McCormack PL. Radium-223 dichloride in castration-resistant prostate cancer with symptomatic bone metastases: a guide to its use. *Drugs Ther Perspect.* 2016;32(3):98–103. doi:[10.1007/s40267-016-0283-8](https://doi.org/10.1007/s40267-016-0283-8)
- Syed YY, Lyseng-Williamson KA, Blair HA, et al. Umeclidinium/vilanterol dry-powder inhaler in chronic obstructive pulmonary disease: a guide to its use in the EU. *Drugs Ther Perspect.* 2016;32(7):276–81. doi:[10.1007/s40267-016-0309-2](https://doi.org/10.1007/s40267-016-0309-2)

I offer my sincere thanks to all authors who have contributed articles to *Drugs & Therapy Perspectives* over the

course of 2016. Their skill and dedication are critical to the continued publication of the journal. The quality of published articles is, similarly, testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal's content is held to the highest possible standard.

I would like to thank the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:

Darrell R. Abernethy, Silver Spring, MD, USA
Christopher P. Alderman, Adelaide, SA, Australia
Yusef A. Alomi, Riyadh, Saudi Arabia
Francisco Araujo, Seville, Spain
Mohamed Baraka, Damman, Saudi Arabia
Aygin Bayrakta-Ekincioglu, Ankara, Turkey
Gabriele Bianchi Porro, Milan, Italy
Margarida Caramona, Coimbra, Portugal
Margarida Castel-Branco, Coimbra, Portugal
Natalie Cebotarenco, Chişinău, Moldova
Surarong Chinwong, Chiang Mai, Thailand
Barbara Claus, Ghent, Belgium
Richard O. Day, Sydney, NSW, Australia
Isabel Vitoria Figueiredo, Coimbra, Portugal
William H. Frishman, Valhalla, NY, USA
David J. Greenblatt, Boston, MA, USA
Mara Guerreiro, Lisbon, Portugal
Martina Hahn, Eltville, Germany
Rob Janknegt, Sittard-Geleen, The Netherlands
Gail Judd, London, ON, Canada
Hannelore Kreckel, Giessen, Germany
Gert Laekeman, Leuven, Belgium
Michel Le Duff, Rennes, France
Micha Levy, Jerusalem, Israel
Howard I. Maibach, San Francisco, CA, USA
Petra Matoulková, Hradec Králové, Czech Republic
Audrey McAnaw, Dundee, Scotland
Tadja Miharija-Gala, Ljubljana, Slovenia
Sanja Mirkov, Melbourne, VIC, Australia
Emina Obarcanin, Düsseldorf, Germany
Gurumurthi Parthasarathi, Mysore, India
Sandeep Saluja, Agra, India
Jerome Schentag, Buffalo, NY, USA
Rima Bharatbhai Shah, India
Kirsten K. Viktil, Oslo, Norway

In addition, I would like to thank the following individuals who also acted as reviewers for articles published in the 2016 issues of *Drugs & Therapy Perspectives*:

Elisabetta Abruzzese, Italy
Alice Acurado, Portugal
A. Deniz Akkaya, Turkey
Emanuele Angelucci, Italy

Yusi Anggriani, Indonesia
Alessandro Antonelli, Italy
Angelo Antonini, Italy
Sabina A. Antoniu, Romania
Venkata S. Atluri, USA
Michele Baccarani, Italy
Harold E. Bays, USA
Meral Beksac, Turkey
Karl-Christian Bergmann, Germany
Lothar Bergmann, Germany
Lise Bernard, France
Daniel G. Bichet, Canada
John E. A. Blair, USA
Corradi Blandizzi, Italy
Bernd Bokemeyer, Germany
Alessandro Borghi, Italy
Ambrogio Bottoni, Italy
Murat Bozlu, Turkey
J. Christopher Bradberry, USA
Marta Benedetta Brumana, Italy
Ana C. Calvo, Spain
Giancarlo Castaman, Italy
Renato Caviglia, Italy
Yuksel Cavusoglu, Turkey
Soju Chang, USA
Jing Chen, China
Luis Costa, Portugal
Phillip Couratier, France
Jordan R. Covvey, USA
Tine L. M. De Backer, Belgium
Javier de la Rubia, Spain
Ronan Desmond, Ireland
Tobias Dreischulte, UK
Gregory Duncan, Australia
Steven R. Feldman, USA
Maria Teresa Ferreira Herdeiro, Portugal
Richard G. Fiscella, USA
Anthony W. Fox, UK
Pierre Fumoleau, France
Bharat Gajjar, India
Arthur F. Gelb, USA
Jalal K. Ghali, USA
Clara E. Green, UK
Fabrizio Guarneri, Italy
Yoshiyuki Hamamoto, Japan
Khedidja Hedna, Sweden
Wayne J.G. Hellstrom, USA
Nusrat Homaira, Australia
Friedrich Horak, Austria
Catherine Hurt, UK
Cristoforo Incorvaia, Italy
John K. Iskander, USA
Edward M. Kerwin, USA

Leon H. Kircik, USA
Eija Kivekas, Finland
Richard Kones, USA
Ines Krass, Australia
Anne Lee, UK
Theresa Leung, Hong Kong
Steven J. Lichtenstein, USA
Hua Ling, USA
José Lopes, Portugal
Giovanni Maconi, Italy
Slawomir Majewski, Poland
Louise Mallet, Canada
Pier Mannuccio Mannucci, Italy
Juan Antonio Martinez Tadeo, Spain
Ana Paula Martins, Portugal
Maria-Victoria Mateos, Spain
Cormac McCarthy, USA
Hideaki Miyoshi, Japan
Anish Nadkarni, USA
Steve E. Nissen, USA
Dag Nyholm, Sweden
Sven-Eric Olsson, Sweden
Arnold P. Oranje, The Netherlands
Clive Page, UK
Farzad Peiravian, Iran
Marek Petras, Czech Republic
Andrea Prodi, Italy
Margaret V. Ragni, USA
Hesty Utami Ramadaniati, Indonesia
Helena Ribeiro, Portugal
Yoshifumi Saisho, Japan
Sujit Vijay Sakpal, USA
Mohammad Saleem, USA
Salvatore Salomone, Italy
Phillip Scheinberg, USA
Ignacio Segarra, Spain
Bruno Sepodes, Portugal
Amit M. Shah, India
Margaret Sheridan-Pereira, Ireland
Gopendra Singh, India
Cassian Sitaru, Germany
Dirk D. Skowasch, Germany

Malcom Steiger, UK
Robert A. Stockley, UK
Maysa Suyagh, Jordan
Andrzej Robert Tomasik, Poland
Thomas E. Wessendorf, Germany
Faysal A. Yafi, USA
Masakazu Yamada, Japan
Nazia Yasmeeen, India
Yildiray Yeniay, Turkey
Robin J. Young, UK
Chao Zhou, The Netherlands

In other portfolio news, the release of the ISI Journal Citation Reports in mid-2016 saw a rise in impact factor against the previous year for the majority of our ISI-indexed journals. Most notably, five of our journals saw an increase of over 10% in impact factor—*The Patient* (17.08%), *Clinical Drug Investigation* (15.99%), the *American Journal of Clinical Dermatology* (13.17% increase), *Drug Safety* (12.52%), and *Drugs* (12.43%).

Another important milestone was reached for our recently launched open access journals, *Drug Safety–Case Reports* and *Drugs–Real World Outcomes*. Content from these journals is now available on PubMed Central.

The Adis journals portfolio will expand in 2017, with the launch of *PharmacoEconomics–Open*. This new journal will be fully open access and will focus on the publication of applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. It joins our other well respected health outcomes publications, *PharmacoEconomics*, *Applied Health Economics & Health Policy* and *The Patient: Patient Centered Outcomes Research*.

I hope that you have found the articles published throughout 2016 to be both interesting and informative. I have appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with topical issues related to rational drug use and disease management in the clinical practice setting in 2017.

With best wishes,
 Katherine Lyseng-Williamson